Agios Pharmaceuticals (NASDAQ:AGIO) Releases Quarterly Earnings Results, Misses Expectations By $0.05 EPS

Agios Pharmaceuticals (NASDAQ:AGIO) released its earnings results on Thursday. The biopharmaceutical company reported ($1.74) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.69) by ($0.05), Zacks reports. Agios Pharmaceuticals had a negative return on equity of 2.51% and a net margin of 1,845.92%.

Agios Pharmaceuticals Stock Up 4.3 %

AGIO opened at $35.22 on Friday. The firm has a market capitalization of $2.02 billion, a P/E ratio of 3.11 and a beta of 0.88. The firm’s 50 day moving average is $34.29 and its 200-day moving average is $43.03. Agios Pharmaceuticals has a 52-week low of $26.66 and a 52-week high of $62.58.

Insider Activity

In other news, insider Tsveta Milanova sold 2,804 shares of Agios Pharmaceuticals stock in a transaction that occurred on Monday, January 6th. The shares were sold at an average price of $32.18, for a total transaction of $90,232.72. Following the sale, the insider now owns 18,906 shares in the company, valued at $608,395.08. This trade represents a 12.92 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Insiders own 4.93% of the company’s stock.

Wall Street Analyst Weigh In

Several equities research analysts recently issued reports on AGIO shares. Scotiabank raised their target price on shares of Agios Pharmaceuticals from $53.00 to $75.00 and gave the stock a “sector outperform” rating in a research report on Monday, December 9th. Cantor Fitzgerald reissued an “overweight” rating on shares of Agios Pharmaceuticals in a research report on Wednesday, December 18th. StockNews.com cut shares of Agios Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Friday, February 14th. Finally, Royal Bank of Canada lifted their price target on shares of Agios Pharmaceuticals from $55.00 to $57.00 and gave the company an “outperform” rating in a research report on Tuesday, December 10th. One equities research analyst has rated the stock with a sell rating, four have assigned a hold rating and four have issued a buy rating to the stock. According to MarketBeat, the stock presently has a consensus rating of “Hold” and an average target price of $56.33.

Agios Pharmaceuticals Company Profile

Agios Pharmaceuticals, Inc, a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias.